Considering the autocrine effect of chemerin on activating NF-κB signaling in TAMs and GBM cells, targeting the chemerin/CMKLR1 axis in GBM could be expected to exert a similar tumor suppressive effect as that with NF-κB inhibition [79]. The gene discussed is RARRES2; the disease is glioblastoma.